OvaStem®
Urogynecological Conditions
PreclinicalResearch
Key Facts
Indication
Urogynecological Conditions
Phase
Preclinical
Status
Research
About Creative Medical Technology Holdings
Creative Medical Technology Holdings is a US-based regenerative medicine and immunotherapy company with a mission to improve patient lives through innovative autologous cell therapies. Its core strategy leverages two disruptive platforms: the ImmCelz™ Supercharged Autologous Immunotherapy platform for modulating immune disorders and a Rapid Autologous Stem Cell platform for orthopedic and degenerative conditions. Recent achievements include an FDA Orphan Drug Designation for ImmCelz™ in Type 1 Diabetes and a Notice of Allowance for a key patent, positioning the company in sizable markets with a potentially differentiated clinical approach.
View full company profile